Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights [Yahoo! Finance]
Shattuck Labs, Inc. (STTK)
Company Research
Source: Yahoo! Finance
Higher-Risk Myelodysplastic Syndromes (HR-MDS) and frontline TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients; initial data build on the dose-escalation data featured in a poster presentation at the American Society of Hematology (ASH) Annual Meeting – - Completed initial enrollment in Phase 1B dose-expansion cohorts for frontline HR-MDS and TP53m AML patients in the fourth quarter of 2023; additional enrollment ongoing, with updated combination data expected mid-year 2024 – - Completed enrollment and presented positive interim data from the Phase 1B clinical trial of SL-172154 in combination with pegylated liposomal doxorubicin (PLD) in platinum-resistant ovarian cancer (PROC), which demonstrated an acceptable safety profile and encouraging anti-tumor activity that compares favorably to PLD as a monotherapy – - Entered into strategic collaboration and license agreement with Ono Pharmaceutical Co., Ltd (Ono) to generate novel bifunctional fusion proteins with the potent
Show less
Read more
Impact Snapshot
Event Time:
STTK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
STTK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
STTK alerts
High impacting Shattuck Labs, Inc. news events
Weekly update
A roundup of the hottest topics
STTK
News
- Shattuck Labs First Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
- Shattuck Labs, Inc. (NASDAQ: STTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.MarketBeat
- Shattuck Labs, Inc. (NASDAQ: STTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $28.00 price target on the stock.MarketBeat
- Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]Yahoo! Finance
STTK
Earnings
- 2/29/24 - Beat
STTK
Sec Filings
- 5/2/24 - Form 10-Q
- 5/2/24 - Form 8-K
- 4/23/24 - Form ARS
- STTK's page on the SEC website